Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 4.9% – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares fell 4.9% during mid-day trading on Thursday . The stock traded as low as $49.2850 and last traded at $49.2850. 330 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 2,757 shares. The stock had previously closed at $51.8050.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZLDPF. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Zacks Research cut Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S presently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Performance

The stock has a market cap of $3.53 billion, a PE ratio of 8.17 and a beta of 0.88. The firm has a 50-day simple moving average of $46.90 and a 200-day simple moving average of $48.30. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.